Further understanding the connection between Alzheimer's disease and Down syndrome
Year: 2020
Type: article
Abstract: Improved medical care of individuals with Down syndrome (DS) has led to an increase in life expectancy to over the age of 60 years. In conjunction, there has been an increase in age-related co-occurring conditions including Alzheimer's disease (AD). Understanding the factors that underlie symptom and age of clinical presentation of dementia in people with DS may provide insights into the mechanisms of sporadic and DS-associated AD (DS-AD). In March 2019, the Alzheimer's Association, Global Down Syndrome Foundation and the LuMind IDSC Foundation partnered to convene a workshop to explore the state of the research on the intersection of AD and DS research; to identify research gaps and unmet needs; and to consider how best to advance the field. This article provides a summary of discussions, including noting areas of emerging science and discovery, considerations for future studies, and identifying open gaps in our understanding for future focus.
Source: Alzheimer s & Dementia
DOI: 10.1002/alz.12112
Authors: Heather M. Snyder, Lisa J. Bain, Adam M. Brickman, Maria C. Carrillo, Anna J. Esbensen, Joaquin M. Espinosa, Fabian Fernandez, Juan Fortea, Sigan L. Hartley, Elizabeth Head, James Hendrix, Priya S. Kishnani, Florence Lai, Patrick Lao, Cynthia Lemere, William Mobley, Elliott J. Mufson, Huntington Potter, Shahid H. Zaman, Ann‐Charlotte Granholm, H. Diana Rosas, Andre Strydom, Michelle Sie Whitten, Michael S. Rafii
Institutions: Alzheimer's Association, Columbia University, Cincinnati Children's Hospital Medical Center, University of Cincinnati, University of Colorado Anschutz, University of Arizona, BIO5 Institute, Universitat Autònoma de Barcelona, Hospital de Sant Pau, Biomedical Research Networking Center on Neurodegenerative Diseases, Institut de Recerca Sant Pau, University of Wisconsin–Madison, University of California, Irvine, Duke University, Duke Medical Center, Harvard University, Massachusetts General Hospital, Columbia University Irving Medical Center, Brigham and Women's Hospital, University of California San Diego, Barrow Neurological Institute, University of Colorado Denver, University of Cambridge, Cambridgeshire and Peterborough NHS Foundation Trust, University of Denver, Karolinska Institutet, King's College London, South London and Maudsley NHS Foundation Trust, Global Down Syndrome Foundation, University of Southern California
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Cure Alzheimer's Fund, Wellcome Trust, Agence Nationale de la Recherche, National Institutes of Health, Medical Research Council, National Institute on Aging, National Institute of Allergy and Infectious Diseases, National Institute of Neurological Disorders and Stroke, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Center for Advancing Translational Sciences, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awards: G1257541548, G1309605592, G2190753515, The Role of Inflammation and NGF Dysfunction in the Evolution of AlzheimerDisease Pathology in Down syndrome, G2580749706, G261741909, Waisman Intellectual and Developmental Disabilities Research Center, G2891325330, G2913662408, G2957681590, Neurobiology of Mild Cognitive Impairment in the Elderly, Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease, G4005162399, Neuropathological and Amyloid peptides differences between Down syndrome and familial Alzheimer’s disease with duplications and missense mutations in APP gene, Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease, G4377920894, Understanding Down Syndrome as an Interferonopathy, G4511376228, G4631517195, The London Down Syndrome Consortium (LonDownS): An integrated system to study the development and therapeutic amelioration of cognition and dementia., JAK Inhibition in Down Syndrome, G535778818, G6848103159, G8085101257, Colorado Clinical and Transational Sciences Institute, ACTIVE IMMUNOTHERAPY FOR COGNITIVE DECLINE IN ADULTS WITH DOWN SYNDROME, Understanding and Mitigating Vascular Side-Effects Associated with Anti-Amyloid Immunotherapy, Alzheimer's Disease Neuroimaging Initiative (ADNI4), National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)
OpenAlex ID: W3035322587